{"id":71946,"date":"2026-08-07T20:30:12","date_gmt":"2026-08-07T12:30:12","guid":{"rendered":"https:\/\/flcube.com\/?p=71946"},"modified":"2026-08-07T20:30:13","modified_gmt":"2026-08-07T12:30:13","slug":"transthera-sciences-secures-nmpa-conditional-approval-for-tinengotinib-in-advanced-cholangiocarcinoma-with-fgfr2-alterations","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=71946","title":{"rendered":"TransThera Sciences Secures NMPA Conditional Approval for Tinengotinib in Advanced Cholangiocarcinoma with FGFR2 Alterations"},"content":{"rendered":"\n<p class=\"wp-block-paragraph\"><strong>TransThera Sciences<\/strong> (<a href=\"https:\/\/www.google.com\/finance\/beta\/quote\/2617:HKG\">HKG: 2617<\/a>) announced that China&#8217;s <strong>National Medical Products Administration (NMPA)<\/strong> has granted <strong>conditional marketing approval<\/strong> for its <strong>Class 1 innovative drug tinengotinib<\/strong>, indicated for the treatment of adult patients with <strong>advanced, metastatic, or unresectable cholangiocarcinoma<\/strong> harboring <strong>fibroblast growth factor receptor (FGFR) 2 fusions or rearrangements<\/strong> who have previously received systemic therapy and FGFR inhibitor treatment.<\/p>\n\n\n\n<h2 id=\"h-regulatory-milestone-amp-status\" class=\"wp-block-heading\">Regulatory Milestone &amp; Status<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Item<\/th><th>Detail<\/th><\/tr><\/thead><tbody><tr><td><strong>Agency<\/strong><\/td><td>NMPA (China)<\/td><\/tr><tr><td><strong>Approval Type<\/strong><\/td><td>Conditional, Class 1 innovative drug<\/td><\/tr><tr><td><strong>Product<\/strong><\/td><td>Tinengotinib (oral small-molecule kinase inhibitor)<\/td><\/tr><tr><td><strong>Indication<\/strong><\/td><td>Advanced cholangiocarcinoma with FGFR2 fusions\/rearrangements post-systemic and FGFR inhibitor therapy<\/td><\/tr><tr><td><strong>Approval Date<\/strong><\/td><td>August 6, 2026<\/td><\/tr><tr><td><strong>Global Designations<\/strong><\/td><td>FDA Orphan Drug + Fast Track; EMA Orphan Drug for biliary tract cancer<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<h2 id=\"h-drug-profile-amp-mechanism-of-action\" class=\"wp-block-heading\">Drug Profile &amp; Mechanism of Action<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Molecule:<\/strong> Novel multi-target small-molecule kinase inhibitor<\/li>\n\n\n\n<li><strong>Targets:<\/strong> <strong>FGFR<\/strong>, <strong>JAK<\/strong>, <strong>VEGFR<\/strong>, and <strong>Aurora<\/strong> kinases<\/li>\n\n\n\n<li><strong>Innovation:<\/strong> Triple-action mechanism through <strong>precise targeting<\/strong>, <strong>lineage remodeling<\/strong>, and <strong>immune activation<\/strong><\/li>\n\n\n\n<li><strong>Intellectual Property:<\/strong> Independently developed by TransThera Sciences with global patent protection<\/li>\n\n\n\n<li><strong>Development Stage:<\/strong> Evaluated across multiple global clinical trials in solid tumors including cholangiocarcinoma, prostate cancer, breast cancer, and liver cancer<\/li>\n<\/ul>\n\n\n\n<h2 id=\"h-clinical-significance-amp-unmet-need\" class=\"wp-block-heading\">Clinical Significance &amp; Unmet Need<\/h2>\n\n\n\n<p class=\"wp-block-paragraph\">Cholangiocarcinoma represents one of the most challenging gastrointestinal malignancies, with limited treatment options particularly for patients who have progressed after standard therapies and FGFR inhibitors. The conditional approval addresses a critical gap in the treatment paradigm for this molecularly-defined subset of patients with FGFR2 alterations.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">Tinengotinib&#8217;s multi-target approach differentiates it from selective FGFR inhibitors by simultaneously modulating tumor cell signaling, microenvironment interactions, and immune responses. This comprehensive mechanism may overcome resistance patterns commonly observed with single-target agents in the refractory setting.<\/p>\n\n\n\n<h2 id=\"h-market-impact-amp-strategic-positioning\" class=\"wp-block-heading\">Market Impact &amp; Strategic Positioning<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Addressable Population:<\/strong> Estimated 15-20% of cholangiocarcinoma patients harbor FGFR2 fusions\/rearrangements<\/li>\n\n\n\n<li><strong>Competitive Landscape:<\/strong> First Chinese-developed multi-kinase inhibitor approved for this specific molecular indication<\/li>\n\n\n\n<li><strong>Global Strategy:<\/strong> Strong regulatory foundation with FDA Fast Track and dual Orphan Drug designations positions tinengotinib for potential international expansion<\/li>\n\n\n\n<li><strong>Revenue Outlook:<\/strong> TransThera projects significant market penetration in China&#8217;s precision oncology segment, with potential for combination therapy development<\/li>\n<\/ul>\n\n\n\n<p class=\"wp-block-paragraph\"><strong>Forward-Looking Statements<\/strong><br>This brief contains forward-looking statements regarding regulatory timelines, clinical outcomes, and commercial expectations for tinengotinib. Actual results may differ due to risks including final approval conditions, market adoption, competitive dynamics, and global regulatory requirements.<a href=\"https:\/\/flcube.com\/\">-Fineline Info &amp; Tech<\/a><\/p>\n\n\n\n<div data-wp-interactive=\"core\/file\" class=\"wp-block-file\"><object data-wp-bind--hidden=\"!state.hasPdfPreview\" hidden class=\"wp-block-file__embed\" data=\"https:\/\/flcube.com\/wp-content\/uploads\/2026\/08\/2026080601840_c.pdf\" type=\"application\/pdf\" style=\"width:100%;height:600px\" aria-label=\"Embed of 2026080601840_c.\"><\/object><a id=\"wp-block-file--media-9d5fbfa5-d6ba-4a30-8408-8a8f68cdc395\" href=\"https:\/\/flcube.com\/wp-content\/uploads\/2026\/08\/2026080601840_c.pdf\">2026080601840_c<\/a><a href=\"https:\/\/flcube.com\/wp-content\/uploads\/2026\/08\/2026080601840_c.pdf\" class=\"wp-block-file__button wp-element-button\" download aria-describedby=\"wp-block-file--media-9d5fbfa5-d6ba-4a30-8408-8a8f68cdc395\">Download<\/a><\/div>\n","protected":false},"excerpt":{"rendered":"<p>TransThera Sciences (HKG: 2617) announced that China&#8217;s National Medical Products Administration (NMPA) has granted conditional&#8230;<\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"googlesitekit_rrm_CAownpewDA:productID":"","_jetpack_newsletter_access":"","_jetpack_dont_email_post_to_subs":false,"_jetpack_newsletter_tier_id":0,"_jetpack_memberships_contains_paywalled_content":false,"_jetpack_feature_clip_id":0,"_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":true,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2},"jetpack_post_was_ever_published":false},"categories":[7,11],"tags":[16,4181,15,601],"class_list":["post-71946","post","type-post","status-publish","format-standard","hentry","category-company","category-drug","tag-cancer","tag-hkg-2617","tag-product-approvals","tag-transthera-sciences"],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v27.5 (Yoast SEO v28.2) - https:\/\/yoast.com\/product\/yoast-seo-premium-wordpress\/ -->\n<title>TransThera Sciences Secures NMPA Conditional Approval for Tinengotinib in Advanced Cholangiocarcinoma with FGFR2 Alterations - Insight, China&#039;s Pharmaceutical Industry<\/title>\n<meta name=\"description\" content=\"TransThera Sciences (HKG: 2617) announced that China&#039;s National Medical Products Administration (NMPA) has granted conditional marketing approval for its Class 1 innovative drug tinengotinib, indicated for the treatment of adult patients with advanced, metastatic, or unresectable cholangiocarcinoma harboring fibroblast growth factor receptor (FGFR) 2 fusions or rearrangements who have previously received systemic therapy and FGFR inhibitor treatment.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/flcube.com\/?p=71946\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"TransThera Sciences Secures NMPA Conditional Approval for Tinengotinib in Advanced Cholangiocarcinoma with FGFR2 Alterations\" \/>\n<meta property=\"og:description\" content=\"TransThera Sciences (HKG: 2617) announced that China&#039;s National Medical Products Administration (NMPA) has granted conditional marketing approval for its Class 1 innovative drug tinengotinib, indicated for the treatment of adult patients with advanced, metastatic, or unresectable cholangiocarcinoma harboring fibroblast growth factor receptor (FGFR) 2 fusions or rearrangements who have previously received systemic therapy and FGFR inhibitor treatment.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/flcube.com\/?p=71946\" \/>\n<meta property=\"og:site_name\" content=\"Insight, China&#039;s Pharmaceutical Industry\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61566606313834\" \/>\n<meta property=\"article:published_time\" content=\"2026-08-07T12:30:12+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2026-08-07T12:30:13+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"2560\" \/>\n\t<meta property=\"og:image:height\" content=\"1894\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"Fineline Cube\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:description\" content=\"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fineline Cube\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=71946#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=71946\"},\"author\":{\"name\":\"Fineline Cube\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\"},\"headline\":\"TransThera Sciences Secures NMPA Conditional Approval for Tinengotinib in Advanced Cholangiocarcinoma with FGFR2 Alterations\",\"datePublished\":\"2026-08-07T12:30:12+00:00\",\"dateModified\":\"2026-08-07T12:30:13+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=71946\"},\"wordCount\":376,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"keywords\":[\"Cancer\",\"HKG: 2617\",\"Product approvals\",\"TransThera Sciences\"],\"articleSection\":[\"Company\",\"Drug\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=71946#respond\"]}],\"copyrightYear\":\"2026\",\"copyrightHolder\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=71946\",\"url\":\"https:\\\/\\\/flcube.com\\\/?p=71946\",\"name\":\"TransThera Sciences Secures NMPA Conditional Approval for Tinengotinib in Advanced Cholangiocarcinoma with FGFR2 Alterations - Insight, China&#039;s Pharmaceutical Industry\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\"},\"datePublished\":\"2026-08-07T12:30:12+00:00\",\"dateModified\":\"2026-08-07T12:30:13+00:00\",\"description\":\"TransThera Sciences (HKG: 2617) announced that China's National Medical Products Administration (NMPA) has granted conditional marketing approval for its Class 1 innovative drug tinengotinib, indicated for the treatment of adult patients with advanced, metastatic, or unresectable cholangiocarcinoma harboring fibroblast growth factor receptor (FGFR) 2 fusions or rearrangements who have previously received systemic therapy and FGFR inhibitor treatment.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=71946#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=71946\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=71946#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/flcube.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"TransThera Sciences Secures NMPA Conditional Approval for Tinengotinib in Advanced Cholangiocarcinoma with FGFR2 Alterations\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"name\":\"Insight, China's Pharmaceutical Industry\",\"description\":\"Fineline Insights, Pharma Clarity\",\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/flcube.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\",\"name\":\"Fineline Infomation and Technology\",\"alternateName\":\"Fineline Info & Tech\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"width\":2560,\"height\":1894,\"caption\":\"Fineline Infomation and Technology\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61566606313834\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\",\"name\":\"Fineline Cube\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"caption\":\"Fineline Cube\"},\"sameAs\":[\"https:\\\/\\\/flcube.com\"],\"url\":\"https:\\\/\\\/flcube.com\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"TransThera Sciences Secures NMPA Conditional Approval for Tinengotinib in Advanced Cholangiocarcinoma with FGFR2 Alterations - Insight, China&#039;s Pharmaceutical Industry","description":"TransThera Sciences (HKG: 2617) announced that China's National Medical Products Administration (NMPA) has granted conditional marketing approval for its Class 1 innovative drug tinengotinib, indicated for the treatment of adult patients with advanced, metastatic, or unresectable cholangiocarcinoma harboring fibroblast growth factor receptor (FGFR) 2 fusions or rearrangements who have previously received systemic therapy and FGFR inhibitor treatment.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/flcube.com\/?p=71946","og_locale":"en_US","og_type":"article","og_title":"TransThera Sciences Secures NMPA Conditional Approval for Tinengotinib in Advanced Cholangiocarcinoma with FGFR2 Alterations","og_description":"TransThera Sciences (HKG: 2617) announced that China's National Medical Products Administration (NMPA) has granted conditional marketing approval for its Class 1 innovative drug tinengotinib, indicated for the treatment of adult patients with advanced, metastatic, or unresectable cholangiocarcinoma harboring fibroblast growth factor receptor (FGFR) 2 fusions or rearrangements who have previously received systemic therapy and FGFR inhibitor treatment.","og_url":"https:\/\/flcube.com\/?p=71946","og_site_name":"Insight, China&#039;s Pharmaceutical Industry","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61566606313834","article_published_time":"2026-08-07T12:30:12+00:00","article_modified_time":"2026-08-07T12:30:13+00:00","og_image":[{"width":2560,"height":1894,"url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","type":"image\/jpeg"}],"author":"Fineline Cube","twitter_card":"summary_large_image","twitter_description":"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM","twitter_misc":{"Written by":"Fineline Cube","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/flcube.com\/?p=71946#article","isPartOf":{"@id":"https:\/\/flcube.com\/?p=71946"},"author":{"name":"Fineline Cube","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a"},"headline":"TransThera Sciences Secures NMPA Conditional Approval for Tinengotinib in Advanced Cholangiocarcinoma with FGFR2 Alterations","datePublished":"2026-08-07T12:30:12+00:00","dateModified":"2026-08-07T12:30:13+00:00","mainEntityOfPage":{"@id":"https:\/\/flcube.com\/?p=71946"},"wordCount":376,"commentCount":0,"publisher":{"@id":"https:\/\/flcube.com\/#organization"},"keywords":["Cancer","HKG: 2617","Product approvals","TransThera Sciences"],"articleSection":["Company","Drug"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/flcube.com\/?p=71946#respond"]}],"copyrightYear":"2026","copyrightHolder":{"@id":"https:\/\/flcube.com\/#organization"}},{"@type":"WebPage","@id":"https:\/\/flcube.com\/?p=71946","url":"https:\/\/flcube.com\/?p=71946","name":"TransThera Sciences Secures NMPA Conditional Approval for Tinengotinib in Advanced Cholangiocarcinoma with FGFR2 Alterations - Insight, China&#039;s Pharmaceutical Industry","isPartOf":{"@id":"https:\/\/flcube.com\/#website"},"datePublished":"2026-08-07T12:30:12+00:00","dateModified":"2026-08-07T12:30:13+00:00","description":"TransThera Sciences (HKG: 2617) announced that China's National Medical Products Administration (NMPA) has granted conditional marketing approval for its Class 1 innovative drug tinengotinib, indicated for the treatment of adult patients with advanced, metastatic, or unresectable cholangiocarcinoma harboring fibroblast growth factor receptor (FGFR) 2 fusions or rearrangements who have previously received systemic therapy and FGFR inhibitor treatment.","breadcrumb":{"@id":"https:\/\/flcube.com\/?p=71946#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/flcube.com\/?p=71946"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/flcube.com\/?p=71946#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/flcube.com\/"},{"@type":"ListItem","position":2,"name":"TransThera Sciences Secures NMPA Conditional Approval for Tinengotinib in Advanced Cholangiocarcinoma with FGFR2 Alterations"}]},{"@type":"WebSite","@id":"https:\/\/flcube.com\/#website","url":"https:\/\/flcube.com\/","name":"Insight, China's Pharmaceutical Industry","description":"Fineline Insights, Pharma Clarity","publisher":{"@id":"https:\/\/flcube.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/flcube.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/flcube.com\/#organization","name":"Fineline Infomation and Technology","alternateName":"Fineline Info & Tech","url":"https:\/\/flcube.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","width":2560,"height":1894,"caption":"Fineline Infomation and Technology"},"image":{"@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61566606313834"]},{"@type":"Person","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a","name":"Fineline Cube","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","caption":"Fineline Cube"},"sameAs":["https:\/\/flcube.com"],"url":"https:\/\/flcube.com\/?author=1"}]}},"jetpack_publicize_connections":[],"jetpack_featured_media_url":"","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/71946","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=71946"}],"version-history":[{"count":1,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/71946\/revisions"}],"predecessor-version":[{"id":71950,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/71946\/revisions\/71950"}],"wp:attachment":[{"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=71946"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=71946"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=71946"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}